Simplex Trading’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-38,607
| Closed | -$2.78M | – | 9984 |
|
|
2025
Q4 | $2.78M | Sell |
38,607
-6,291
| -14% | -$406K | ﹤0.01% | 1714 |
|
|
2025
Q3 | $1.96M | Buy |
44,898
+42,002
| +1,450% | +$1.7M | ﹤0.01% | 2347 |
|
|
2025
Q2 | $82K | Buy |
+2,896
| New | +$86.3K | ﹤0.01% | 5431 |
|
|
2024
Q3 | – | Sell |
-8,703
| Closed | -$378K | – | 9413 |
|
|
2024
Q2 | $355K | Sell |
8,703
-2,303
| -21% | -$66.1K | ﹤0.01% | 4036 |
|
|
2024
Q1 | $280K | Buy |
+11,006
| New | +$172K | ﹤0.01% | 4484 |
|
|
2023
Q3 | – | Sell |
-11,972
| Closed | -$103K | – | 9647 |
|
|
2023
Q2 | $132K | Buy |
11,972
+2,725
| +29% | +$34.2K | ﹤0.01% | 4754 |
|
|
2023
Q1 | $141K | Buy |
9,247
+7,941
| +608% | +$175K | ﹤0.01% | 4754 |
|
|
2022
Q4 | $28K | Buy |
1,306
+1,174
| +889% | +$17.5K | ﹤0.01% | 6555 |
|
|
2022
Q3 | $2K | Buy |
+132
| New | +$2.52K | ﹤0.01% | 9343 |
|
|
2022
Q1 | – | Sell |
-88
| Closed | -$1.5K | – | 11244 |
|
|
2021
Q4 | $2K | Buy |
+88
| New | +$2.1K | ﹤0.01% | 10043 |
|
Other funds holding RNAM
Simplex Trading's RNAM Position: Q1 2026 in Review
Simplex Trading sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 38,607 shares — an estimated $2.78M sold.
Simplex Trading first reported a position in RNAM in Q4 2021 and held it in 10 quarters. The position peaked at $2.78M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Simplex Trading reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Simplex Trading sold 38,607 Avidity Biosciences shares in Q1 2026, an estimated $2.78M.
- Simplex Trading first reported a position in Avidity Biosciences in Q4 2021 and held it in 10 quarters.
- Simplex Trading's Avidity Biosciences position peaked at $2.78M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.